Notes 1-5
- 1 Operating profit
- 2 Restructuring and synergy costs
- 3 Finance income and expense
- 4 Taxation
- 5 Earnings per $0.25 Ordinary Share
1 OPERATING PROFIT
| 2007 $m |
2006 $m |
2005 $m |
|
|---|---|---|---|
| Group operating profit | 8,094 | 8,216 | 6,502 |
| Charges included above | |||
| – for depreciation | (1,076) | (950) | (965) |
| – for amortisation | (554) | (325) | (272) |
| – for impairment | (226) | (70) | (90) |
| Gross profit | 23,140 | 20,916 | 18,594 |
Impairment charges in 2007 relate to productivity initiatives in the Global Supply Chain in Germany, the write-down of business support assets, the termination of a product in development acquired with MedImmune and four collaboration agreements.
Impairment charges in 2006 relate to the write-down of assets in respect of Toprol-XL, NXY-059 and a collaboration agreement.
Impairment charges in 2005 relate to the write-down of assets associated with capacity reviews at manufacturing sites, primarily in the UK and France.
| 2007 $m |
2006 $m |
2005 $m |
|
|---|---|---|---|
| Other operating income and expense | |||
| Royalties | 236 | 327 | 165 |
| Other income and expense | 492 | 197 | 28 |
| 728 | 524 | 193 | |
Other income and expense includes gains and losses arising from disposals under ongoing product and investment rationalisation programmes.
